Analysis of Antibiotic Outcomes for Hospitalized Adults with Pneumonia at Melati General Hospital, Indonesia
Jurnal Kesehatan · 21.11.2026 · 311-322
DOI: 10.23917/jk.v19i3.21315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Jurnal Kesehatan, online erschienen am 21.11.2026. Verfasst von Fitri Nirwana Sinaga und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pendahuluan: Biaya antibiotik di rumah sakit dan lama rawat inap (length of stay/LOS) merupakan aspek penting dalam penatalaksanaan pneumonia. Namun, bukti lokal yang membandingkan levofloksasin, ceftriaxone, dan cefotaxime di Rumah Sakit Umum Melati masih belum tersedia. Studi ini menganalisis rekam medis tahun 2018 untuk mendeskripsikan penggunaan antibiotik, biaya, lama rawat inap, serta estimasi eksploratif ACER/ICER, tanpa memberikan rekomendasi pengobatan terkini. Metode: Studi retrospektif di satu pusat layanan kesehatan ini menganalisis rekam medis 100 pasien rawat inap dewasa yang dikelompokkan berdasarkan tiga rejimen antibiotik yang tercatat. Biaya antibiotik dan lama rawat inap diringkas, dan perbedaan antar-kelompok diuji menggunakan uji Kruskal-Wallis dan chi-square. Nilai epsilon-squared, Cramer's V, dan interval kepercayaan 95% disertakan untuk mengukur besaran efek dan ketidakpastian. ACER dan ICER dihitung per poin persentase dari luaran operasional berupa lama rawat inap singkat (LOS ≤6 hari), yang bukan merupakan ukuran kesembuhan yang tervalidasi. Hasil: Levofloksasin, ceftriaxone, dan cefotaxime tercatat digunakan masing-masing pada 22, 46, dan 32 pasien. Rata-rata biaya antibiotik adalah Rp545.454,55; Rp535.652,17; dan Rp568.750,00, dengan tidak ditemukan perbedaan signifikan secara keseluruhan (H = 4,462; p = 0,107; epsilon-squared = 0,025). Lama rawat inap singkat terjadi pada 90,9%, 45,7%, dan 84,4% pasien di masing-masing kelompok (chi-square = 19,807; p < 0,001; Cramer's V = 0,445). Nilai ACER masing-masing adalah Rp6.000,60; Rp11.721,05; dan Rp6.738,74 per poin persentase, sementara perbedaan risiko antara levofloksasin dan sefotaksim adalah 6,5 poin (IK 95%, -14,1 hingga 23,9). Kesimpulan: Pola lama rawat inap (LOS) bervariasi antar kelompok, sedangkan biaya antibiotik tidak menunjukkan perbedaan yang signifikan. Meskipun levofloksasin memiliki nilai ACER eksploratif terendah, keunggulan secara klinis maupun ekonomi belum dapat dipastikan karena adanya keterbatasan terkait LOS, komponen biaya yang terbatas, serta faktor perancu (confounding) yang belum disesuaikan. Temuan ini mencerminkan asosiasi deskriptif historis.
Introduction
Hospital antibiotic charges and length of stay (LOS) are important in pneumonia management. However, local evidence comparing levofloxacin, ceftriaxone, and cefotaxime at Melati General Hospital was lacking. This study analyzed 2018 medical records to describe antibiotic utilization, charges, LOS, and exploratory ACER/ICER estimates, without making current treatment recommendations.
Method
This retrospective single-center study analyzed 100 adult inpatient records grouped by the three documented antibiotic regimens. Antibiotic charges and LOS were summarized, and between-group differences were examined using Kruskal-Wallis and chi-square tests. Epsilon-squared, Cramer's V, and 95% confidence intervals were added to quantify effect magnitude and uncertainty. ACER and ICER were calculated per percentage point of an operational short-stay outcome (LOS ≤6 days), not a validated measure of cure.
Results
Levofloxacin, ceftriaxone, and cefotaxime were recorded in 22, 46, and 32 patients, respectively. Mean antibiotic charges were IDR 545,454.55, 535,652.17, and 568,750.00, with no significant overall difference (H = 4.462; p = 0.107; epsilon-squared = 0.025). Short stays occurred in 90.9%, 45.7%, and 84.4% of the groups (chi-square = 19.807; p < 0.001; Cramer's V = 0.445). ACERs were IDR 6,000.60, 11,721.05, and 6,738.74 per percentage point, respectively, while the levofloxacin-cefotaxime risk difference was 6.5 points (95% CI, -14.1 to 23.9).
Conclusion
LOS patterns varied across groups, while antibiotic charges did not differ significantly. Although levofloxacin had the lowest exploratory ACER, clinical or economic superiority was not established due to LOS limitations, restricted cost components, and unadjusted confounding. Findings represent historical descriptive associations.
Zitieren
APA
Sinaga, F. N., Ginting, C. N., & Nasution, S. W. (2026). Analysis of Antibiotic Outcomes for Hospitalized Adults with Pneumonia at Melati General Hospital, Indonesia. Jurnal Kesehatan, 311-322. https://doi.org/10.23917/jk.v19i3.21315
Vancouver
Sinaga FN, Ginting CN, Nasution SW. Analysis of Antibiotic Outcomes for Hospitalized Adults with Pneumonia at Melati General Hospital, Indonesia. Jurnal Kesehatan. 2026:311-322. doi:10.23917/jk.v19i3.21315
BibTeX
@article{Sinaga2026,
author = {Sinaga, Fitri Nirwana and Ginting, Chrismis Novalinda and Nasution, Sri Wahyuni},
title = {Analysis of Antibiotic Outcomes for Hospitalized Adults with Pneumonia at Melati General Hospital, Indonesia},
journal = {Jurnal Kesehatan},
year = {2026},
pages = {311--322},
doi = {10.23917/jk.v19i3.21315}
}
EUVIMED